Department of Nuclear Medicine, Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul 110-744, South Korea.
Nucl Med Biol. 2010 Nov;37(8):893-902. doi: 10.1016/j.nucmedbio.2010.06.003. Epub 2010 Sep 15.
We developed amino acid derivatives of 1,4,7,10-tetraazacyclododecane-1,7-diacetic acid (DO2A) and 1,4,7,10-tetraazacyclododecane-1,4,7,-triacetic acid (DO3A) that can be labeled with (68)Ga, and we investigated their basic biological properties.
Alanine derivatives of DO2A and DO3A were synthesized by regiospecific nucleophilic attack of DO2tBu and DO3tBu on the β-position of Boc-l-serine-β-lactone, followed by acid hydrolysis. Also, homoalanine derivatives were synthesized by reacting with the protected bromo derivative of homoalanine, which was synthesized from N-Cbz-l-homoserine lactone. Further catalytic reduction and acid cleavage of protected groups resulted in the required products. All derivatives were labeled with (68)Ga. Cell uptake assays were carried out in Hep3B (human hepatoma) and U87MG (human glioma) cell lines at 37°C. Positron emission tomography (PET) imaging studies were performed using balb/c mice xenografted with CT-26 (mouse colon cancer).
All compounds were labeled with >97% efficiency. According to in vitro studies, the labeled amino acid derivatives showed significantly greater uptakes than the control ((68)Ga 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) in cancer cells. Small animal PET images for labeled compounds showed high tumor uptake, as well as kidney and bladder uptakes, at 30 min postinjection. (68)Ga-DO3A-homoalanine showed the highest standardized uptake value ratio (3.9 ± 0.3), followed by (68)Ga-DO2A-alanine (3.1 ± 0.2), (68)Ga-DO3A-alanine (2.8 ± 0.2) and (68)Ga-DO2A-homoalanine (2.3 ± 0.2).
These derivatives were found to have high labeling efficiencies, high stabilities, high tumor cell uptakes, high tumor/nontumor xenograft uptakes and low nonspecific uptake in normal organs, except for the kidneys. However, the uptake mechanism of these derivatives remains unclear, and uptake via specific amino acid transporters needs to be demonstrated.
我们开发了 1,4,7,10-四氮杂环十二烷-1,7-二乙酸(DO2A)和 1,4,7,10-四氮杂环十二烷-1,4,7,-三乙酸(DO3A)的氨基酸衍生物,可与 (68)Ga 标记,我们研究了它们的基本生物学特性。
通过 Boc-l-丝氨酸-β-内酰胺的β位的 DO2tBu 和 DO3tBu 的区域特异性亲核攻击,合成 DO2A 和 DO3A 的丙氨酸衍生物,然后进行酸水解。此外,通过与 N-Cbz-l-高丝氨酸内酯合成的保护溴代同源丙氨酸的反应合成同源丙氨酸衍生物。进一步的催化还原和保护基团的酸裂解得到所需产物。所有衍生物均用 (68)Ga 标记。在 Hep3B(人肝癌)和 U87MG(人神经胶质瘤)细胞系中,在 37°C 下进行细胞摄取实验。使用 BALB/c 小鼠异种移植 CT-26(小鼠结肠癌)进行正电子发射断层扫描(PET)成像研究。
所有化合物的标记效率均>97%。根据体外研究,与对照((68)Ga 1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸)相比,标记的氨基酸衍生物在癌细胞中表现出明显更高的摄取率。标记化合物的小动物 PET 图像显示,在注射后 30 分钟,肿瘤摄取以及肾脏和膀胱摄取均很高。(68)Ga-DO3A-同型丙氨酸的标准化摄取比值最高(3.9±0.3),其次是 (68)Ga-DO2A-丙氨酸(3.1±0.2)、(68)Ga-DO3A-丙氨酸(2.8±0.2)和 (68)Ga-DO2A-同型丙氨酸(2.3±0.2)。
这些衍生物具有高标记效率、高稳定性、高肿瘤细胞摄取率、高肿瘤/非肿瘤异种移植摄取率和正常器官中低非特异性摄取率,除肾脏外。然而,这些衍生物的摄取机制尚不清楚,需要证明其通过特定的氨基酸转运体摄取。